Antibacterial activity of LCB01-0062, a novel oxazolidinone.
LCB01-0062, a novel oxazolidinone, has potent antibacterial activity against clinical isolates of Gram-positive bacteria. The in vitro activity of LCB01-0062 was compared with that of linezolid, oxacillin, erythromycin, ciprofloxacin, vancomycin and quinupristin/dalfopristin. Among the tested agents, LCB01-0062 showed the most potent antibacterial activity against meticillin-resistant Staphylococcus aureus, meticillin-resistant coagulase-negative staphylococci and vancomycin-resistant enterococci. LCB01-0062 was 4-8-fold more active than linezolid, the first oxazolidinone drug, against Gram-positive bacteria. The time-kill curves of LCB01-0062 were analysed at concentrations of 0.5×, 1×, 2×, 4× and 8× the minimum inhibitory concentration against S. aureus strains. LCB01-0062 showed bacteriostatic activity during 24 h. LCB01-0062 was also more effective than linezolid against S. aureus in a systemic mouse model of infection.
School of Life Science, Handong Global University, Pohang 791-708, South Korea.
Sung-Ji
SJ
Jung
I-Na-Rae
IN
Yun
Hee Soo
HS
Park
Hyun-Hee
HH
Lee
Ji-Woong
JW
Jeong
Yong-Zu
YZ
Kim
Young-Lak
YL
Cho
Jin-Hwan
JH
Kwak
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D015394:Molecular Structure; D023303:Oxazolidinones / Q000494:pharmacology*; D013997:Time Factors
D000900:Anti-Bacterial Agents; D023303:Oxazolidinones